<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485328</url>
  </required_header>
  <id_info>
    <org_study_id>labsaude-001-ama</org_study_id>
    <nct_id>NCT01485328</nct_id>
  </id_info>
  <brief_title>Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics</brief_title>
  <acronym>AMARGOL</acronym>
  <official_title>Phase III - Efficacy Study of AMARGOL - Phytomedicine on Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorio Saude Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Phytopharm Consulting Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorio Saude Ltda.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3: Efficacy Study for AMARGOL® a phytomedicine used for asymptomatic
      digestive complaints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed for proving the efficacy of AMARGOL®, a phytomedicine product,
      under the Brazilian law for registration and revalidation RDC 14/2010.

      AMARGOL® indications are for non specific digestive complaints as laxative and
      anti-dyspeptic.

      Is a mixture of 7 plant extracts: Aloe ferox, Angelica archangelica, Alpinia officinarum,
      Cinnamomum zeylanicum, Gentiana lutea, Commiphora myrrh and Rheum palmatum.

      Placebo controlled test
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS - visual analogue scale</measure>
    <time_frame>24h</time_frame>
    <description>Single dose 40mL AMARGOL 20 minutes before Dinner - strong meal</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Digestive System Disorders</condition>
  <arm_group>
    <arm_group_label>AMARGOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>per oral solution 40 mL single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle without active principles</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>per oral solution 40 mL single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMARGOL®</intervention_name>
    <description>per oral solution, 40 mL single dose</description>
    <arm_group_label>AMARGOL</arm_group_label>
    <arm_group_label>Vehicle without active principles</arm_group_label>
    <other_name>AMARGOL</other_name>
    <other_name>Phytomedicine</other_name>
    <other_name>Herbal Extracts Mixture</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years old

          -  65-85 Kg

          -  healthy volunteers

        Exclusion Criteria:

          -  chronic dyspeptics illness chronic congestive cardiac problems

          -  pulmonary problems

          -  diabetes, thyroid problems

          -  pregnancy

          -  bowel syndrome

          -  hemorrhoids

          -  colitis

          -  allergies for any formula components.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo G Chaves, Doctor</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Phytopharm Consulting</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90130-021</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyspepsia</keyword>
  <keyword>Flatulence</keyword>
  <keyword>Aerophagia</keyword>
  <keyword>Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coal Tar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

